Full-Time
Cloud-based platform for life sciences R&D
$141.1k - $190.9k/yr
Mid
San Francisco, CA, USA
Hybrid
Employees are expected to be on-site 3 days per week.
Benchling offers a platform for life sciences research and development, catering to biotech and pharmaceutical companies, academic institutions, and research organizations. Its cloud-based tools, including an electronic lab notebook and molecular biology tools, help scientists manage data, collaborate, and streamline workflows. The company operates on a subscription model with various pricing tiers and provides tailored enterprise solutions. Benchling's goal is to enhance the efficiency of scientific research, enabling clients to accelerate their innovations.
Company Size
501-1,000
Company Stage
Series F
Total Funding
$412M
Headquarters
San Francisco, California
Founded
2012
Help us improve and share your feedback! Did you find this helpful?
Four months of fully paid parental leave
401(k) plan
Remote working stipend
Yearly company-wide retreat
Monthly gym and wellness stipend
Commuter benefits
100% premiums covered for health, dental, and vision
Weekly company social events
Flexible PTO and company-wide winter holiday shutdown
Unified platform drives bioanalytical capacity, throughput, and efficiency in regulated environment SAN FRANCISCO, June 11, 2025 /PRNewswire/ -- Benchling announced a new collaboration with Merck, known as MSD outside of the United States and Canada, to implement a software framework that helps bring Merck's pre-clinical and clinical bioanalytical workflows onto one flexible, fully integrated platform. The collaboration focuses on three key areas: enhancing speed and throughput with automated data capture and integration; streamlining with a unified platform for managing workflows and data across the bioanalytical lifecycle; and maintaining rigorous quality and compliance standards in a regulated bioanalytical setting. "Our work with Merck demonstrates how technology and thoughtful collaboration can help address key scientific needs in bioanalysis," said Sajith Wickramasekara, co-founder and CEO of Benchling. "By focusing on the modern demands of bioanalytical labs, we're delivering an approach that aims to enhance efficiency throughout the vaccine development lifecycle." "Sophisticated data management capabilities are integral to advancing vaccine research and development," said Roy Helmy, Associate Vice President, Regulated Bioanalytics at Merck Research Laboratories. "We're thrilled to collaborate with the team at Benchling on a digital integration that enables our scientists to access, analyze, and harness data insights throughout the development process." About Benchling Benchling creates the software that powers the biotechnology industry, serving cutting-edge start-ups and more than half of the top 50 global biopharma companies. Over 200,000 scientists rely on the Benchling RD Cloud as their central source of truth for scientific data, analysis, and collaboration
SAN FRANCISCO and BOSTON, May 7, 2025 - Benchling, the R&D platform powering the biotech industry, today announced an expanded collaboration with Moderna.
We’re excited to announce Benchling’s acquisition of PipeBio, a leader in high-throughput bioinformatics analysis, to drive biologics discovery.
The collaboration is expected to improve the efficiency of the discovery process by combining PipeBio's advanced sequence analysis tools with Benchling's established software ecosystem.
In a significant move to streamline its R&D operations, Novonesis, a global leader in biosolutions, has selected Benchling as its digital platform to enhance the discovery, development, and testing processes across its scientific teams.